Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Keytruda
|
| gptkbp:advocates_for |
obtained
|
| gptkbp:allows |
acknowledged in publications
|
| gptkbp:analysis |
conducted at 12 months
performed by independent committee |
| gptkbp:analyzes |
multiple clinical researchers
|
| gptkbp:business_model |
obtained
|
| gptkbp:clinical_trial |
improved survival rates
|
| gptkbp:collaborations |
international research teams
various oncology centers |
| gptkbp:collection |
prospective
|
| gptkbp:complications |
guiding treatment decisions
|
| gptkbp:criteria |
previous treatment with anti-PD-1 or anti-PD-L1
histologically confirmed non-small cell lung cancer |
| gptkbp:depicted_in |
ensured
|
| gptkbp:duration |
at least 2 years
up to 35 cycles |
| gptkbp:finale_date |
overall survival
progression-free survival |
| gptkbp:focus |
chemotherapy
|
| gptkbp:future_plans |
exploring combination therapies
investigating long-term effects |
| gptkbp:healthcare |
NC T02578680
|
| https://www.w3.org/2000/01/rdf-schema#label |
KEYNOTE-189
|
| gptkbp:impact |
changed treatment guidelines
|
| gptkbp:is_studied_in |
multicenter, randomized, controlled trial
|
| gptkbp:is_tested_for |
Phase 3
PD-L1 expression |
| gptkbp:launch_date |
gptkb:2017
|
| gptkbp:location |
multiple countries
|
| gptkbp:participants |
quality of life
|
| gptkbp:population |
diverse population
approximately 600 patients |
| gptkbp:products |
gptkb:pembrolizumab
|
| gptkbp:provides_information_on |
pembrolizumab plus chemotherapy
|
| gptkbp:publishes |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:receives_funding_from |
provided by Merck & Co.
|
| gptkbp:recorded_by |
1:1 ratio
|
| gptkbp:regulatory_compliance |
FDA approval for pembrolizumab
|
| gptkbp:research |
widely cited
presented at conferences |
| gptkbp:research_focus |
gptkb:vaccine
|
| gptkbp:result |
gptkb:2020
positive with regulatory agencies |
| gptkbp:safety_features |
acceptable
|
| gptkbp:side_effect |
gptkb:significant
monitored |
| gptkbp:significance |
p<0.001
|
| gptkbp:social_responsibility |
gptkb:healthcare_organization
|
| gptkbp:sponsor |
gptkb:Merck_&_Co.
|
| gptkbp:student_enrollment |
completed ahead of schedule
|
| gptkbp:target_audience |
patients with metastatic non-small cell lung cancer
|
| gptkbp:treatment |
gptkb:pembrolizumab
|
| gptkbp:vision |
double-blind
|
| gptkbp:warranty |
ongoing
|
| gptkbp:year |
gptkb:2020
|